Medpace Holdings Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Medpace Holdings Inc trades at $598 (market cap $16.90B), while Consumer Staples Select Sector SPDR Fund trades at $85.17. The key difference: Medpace Holdings Inc is trading nearer its 52-week high, Consumer Staples Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| MEDP | XLP | |
|---|---|---|
Market Cap | $16.90B | — |
Sector | Technology | — |
52-Week High | $620.59 | $90.00 |
52-Week Low | $393.42 | $75.61 |
Enterprise Value | $16.52B | — |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
XLP trades at $85.08 with minimal daily movement (+0.15%), reflecting stable defensive positioning. Technical indicators show mixed signals with a neutral overall rating, while analyst consensus remains strongly bullish with 100% buy ratings. The consumer staples ETF benefits from recent positive sector momentum and defensive characteristics during market uncertainty.
The outlook remains positive given the defensive nature of consumer staples amid economic uncertainty, with potential for steady dividend income. Key risks include sector rotation away from defensive plays and valuation concerns if growth expectations moderate. The 2.6% dividend yield provides income support while awaiting capital appreciation.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →